sector medic suppli devic
 fire cylind head
rais pt reiter buy
messag tone abbott call bullish heard time
deservedli view one year complet transform deal st
jude abbott emerg one best growth stori large-cap med-tech
expect quarter organ revenu growth norm go forward
see clear pathway top bottom line gain least
outlook believ warrant premium multipl rais price target
reiter buy rate best idea design
st jude mend abbott enter fire cylind three
compani four busi segment top street estim led medic
devic franchis cardio neuro growth improv organ first nine
month year driven primarili improv perform
rhythm manag easi yoy comp help estim abbott also
gain share sequenti icd pacemak view encourag
especi sinc earlier month compani mri label
across full icd/crt-d product line note growth legaci
st jude busi outsid remain robust organ averag
sinc even issu cloud overal compani perform
rhythm manag back least modest growth strength
franchis shine model call abbott overal medic devic
segment deliv organ growth driven primarili
acceler cardio neuro sale vs
meanwhil libr continu demonstr impress momentum europ
 launch get underway intern libr revenu came
sharpli sale top believ product
could approach revenu ou recent posit coverag decis
uk japan particular open larg new market opportun suggest
us libr still ampl runway left intern despit remark success
alreadi enjoy turn believ high end manag
direct guidanc rang could play follow posit coverag
decis earlier month non-medicar patient still need pay pocket
commerci reimburs establish believ low up-front cost
system encourag trial although may take abbott month build
critic mass reimburs front continu see libr superior econom
someth payer eventu embrac similar experi europ
abbott turn solid outsid devic well nutrit laggard
quarter mere meet street expect also divis weakest
growth outlook yet even stori one improv recent
enact infant formula regul china set drive acceler pediatr growth
next quarter estim abbott overal chines nutrit busi
declin roughli driven primarili flood
cheap formula inventori brought market wake chines govern
decis impos stricter rule qualiti number brand produc
one manufactur facil regul final effect start begin
year believ abbott posit take share smaller competitor exit
market assum benefit partial off-set moder
 pediatr growth grew like unsustain clip net effect
still meaning acceler busi overal model call
world-wide pediatr nutrit sale rise gain
continu page
page analyst certif import disclosur
elsewher alin drive continu momentum diagnost
roll-out europ measur date pick steam next
quarter meanwhil abbott first assay approv prepar
launch system domest kick multi-year
upgrad cycl manag believ allow sustain underli growth
diagnost busi go forward aler also better expect
start contribut revenu vs manag initi estim
driven part strong cold flu season chairman ceo mile white
character aler turnaround long-term project one abbott took
st jude note integr track ahead plan thu far
continu think busi potenti exceed rel low street
expect given strong strateg fit abbott point segment final
although rel lack visibl compani establish pharma busi
sometim sourc frustrat investor result tough complain
epd post anoth doubl digit growth year account
impact tax chang india wednesday call mr white express confid
compani abil sustain underli growth rate go forward
net view sustain growth outlook
abbott overal leverag low-to-mid teen gain bottom line
model call adjust ep total revenu
organ prior outlook respect
put abbott comfort large-cap med-tech averag growth rate
top bottom line premium growth outlook least partial
reflect stock today share trade ntm ep estim vs
group continu see potenti modest multipl expans
combin strong earn outlook posit stock well continu
out-performance move view rais price
target base multipl previous
forward ntm ep estim signific upsid potenti target current
level reiter buy rate
page analyst certif import disclosur
abbott one largest healthcar compani world boast top line
lead franchis across medic devic diagnost nutrit establish
pharmaceut segment path get point long wind one
abbott reshuffl portfolio sever time past two decad recent
acquisit st jude medic aler dust settl deal
see abbott emerg premium grower within large-cap med-tech group
model call compani deliv top bottom line gain
respect compar averag peer yet
stock trade today modest premium group ntm ep vs
provid opportun rel multipl expans visibl st jude
aler integr improv growth acceler time med-tech investor
struggl find valu multipl high see attract
abbott share current trade ntm ep estim ntm
ebitda modestli large-cap med-tech averag
respect believ abbott above-averag growth profil peg
top bottom line respect vs group averag
warrant premium valuat price target previous
base multipl previous forward ntm ep
estim signific upsid potenti target current level assign
downsid risk rate price target includ integr challeng relat
st jude aler acquisit pipelin setback and/or neg clinic result
impact abbott competit adopt key new product libr alin
etc fall short street expect
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
point
compani report guggenheim secur llc estim
page analyst certif import disclosur
